Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711346 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells
A Phase 2 study, sponsored by Cerus Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01711346 is a Phase 2 study that has completed, run by Cerus Corporation. The registered enrollment target is 42 participants.
The verdict
NCT01711346, a Phase 2 study, has completed, sponsored by Cerus Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The objective of this study is to assess the post-infusion viability of S-303 Red Blood Cells (RBC) by measuring the 24 hour post-infusion recovery and lifespan of autologous RBCs prepared with the S-303 Treatment System for RBC after storage for 35 days in comparison to conventional untreated RBCs stored for 35 days.
Interventions
- BIOLOGICAL S303 Red Blood Cells (RBCs)
- BIOLOGICAL Conventional, untreated Red Blood Cells (RBCs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711346
The ClinicalTrials.gov registry entry for NCT01711346 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerus Corporation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which S303 Red Blood Cells (RBCs) is the first listed.
NCT01711346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01711346 about?
NCT01711346 is a clinical study titled "A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells". The objective of this study is to assess the post-infusion viability of S-303 Red Blood Cells (RBC) by measuring the 24 hour post-infusion recovery and lifespan of autologous RBCs prepared with the S-303 Treatment System for RBC after storage for 35 days in comparison to conventional untreated RBCs ...
What is the current status of trial NCT01711346?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2012-10. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01711346?
The interventions under investigation include: S303 Red Blood Cells (RBCs) (BIOLOGICAL), Conventional, untreated Red Blood Cells (RBCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01711346?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.